Follow Ciliatech’s past history and latest exciting developments via the news stories below.
First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma Substantial IOP lowering effect from stand-alone procedure Surgical placement of suprachoroidal device without penetrating anterior chamber of eye, irrespective of patients’
The following article, originally published by The Ophthalmologist, provides valuable insights into nurturing innovation in glaucoma surgery. Full credit goes to the original author and publication. You can read the original article here. How one ophthalmologist’s decades-long experience led to the invention of an innovative supraciliary device Over the last
By: Philippe Sourdille, MD GLAUCOMA PHYSICIAN MARCH 1, 2024 VOL OPHTHALMOLOGY MANAGEMENT 28, ISSUE MARCH 2024PAGE(S): E1-E3 A new device grows the glaucoma arsenal while potentially preventing endothelial cell loss and inflammation Glaucoma is characterized by optic nerve damage due to elevated intraocular pressure (IOP) and poses a risk of
Sahil joined the Ciliatech senior leadership team in January 2024 as Global Vice President, Glaucoma Sales & Marketing. Sahil brings with him over 25 years of award-winning industry experience in Ophthalmology and specifically in the glaucoma field having worked for some of the largest companies in the industry including Novartis,
Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform. Chavanod (near Annecy), France, December 5, 2023 – Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces the release of
Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. The different techniques of minimally invasive glaucoma surgery (MIGS) that have been developed for the management of open-angle glaucoma with a gonioscopic ab interno approach, are not applicable in case of a shallow
Ciliatech presents preliminary one-year study results on treating open and narrow angle glaucoma with CID at Ophthalmology Futures Symposium. Preliminary 12-month results show excellent performance and safety profile CID glaucoma implant works similarly in both open and narrow angle glaucoma patients, without the need to remove lens 86% of patients
You will be the 2nd employee of the Company, reporting directly to the CEO, and in close connection with the medical Director.
Prevalence of glaucoma Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form, Primary Open-Angle Glaucoma (POAG), affects more than 3% of people aged 40 years or older. Prevalence increases with age. In people
At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID). The device, a 26% hydrophilic acrylic implant, is designed to lower intraocular pressure without entering the anterior chamber and without
This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.